UT SB0222

Expands patient eligibility for investigational drugs and devices beyond terminal illness to include "eligible illness," defined as conditions presenting substantial, severely debilitating or life-threatening risk with no satisfactory conventional treatment options

Adds cancer diagnosed by a board-certified oncologist as a qualifying terminal illness condition

Requires investigational drugs and devices used for eligible illness (non-terminal) to be currently undergoing FDA-compliant clinical investigations under 21 C.F.R. Parts 312 or 812

Creates new manufacturer reporting requirement to the Health and Human Services Interim Committee by November 1 annually, including patient numbers, illnesses treated, and adverse outcomes

Takes effect May 6, 2026